Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | MMP1 | P03956 | 2/20 | 0.42 |
| ▸ | MMP9 | P14780 | 2/20 | 0.42 |
| ▸ | MMP13 | P45452 | 2/20 | 0.42 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.41 |
| ▸ | PTPRA | P18433 | 1/20 | 0.41 |
| ▸ | PTPRB | P23467 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 2/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6093963 | 1.00 | SLC6A2 (0.50) | SLC6A2TAAR1SMN1; SMN2HIF1AMMP1 | |
| SCHEMBL971950 | 0.84 | SLC6A2 (0.52) | SLC6A2TAAR1SMN1; SMN2HIF1AMMP1 | |
| SCHEMBL10661517 | 0.82 | SMN1; SMN2 (0.48) | SLC6A2TAAR1SMN1; SMN2HIF1AMMP1 | |
| Phentermine SCHEMBL28338903 | 0.78 | SLC6A2 (0.76) | SLC6A2TAAR1SMN1; SMN2HIF1AMMP1 | |
| SCHEMBL5465236 | 0.78 | SLC6A2 (0.48) | SLC6A2TAAR1SMN1; SMN2HIF1AMMP1 | |
| SCHEMBL4127162 | 0.77 | PTPN2 (0.40) | SLC6A2TAAR1SMN1; SMN2HIF1AMMP1 | |
| Sulfuric Acid SCHEMBL5465234 | 0.77 | SLC6A2 (0.55) | SLC6A2TAAR1SMN1; SMN2HIF1AMMP1 | |
| Phentermine SCHEMBL28815884 | 0.77 | SLC6A2 (0.73) | SLC6A2TAAR1SMN1; SMN2HIF1AMMP1 | |
| SCHEMBL10397637 | 0.75 | PTPN2 (0.40) | SLC6A2TAAR1SMN1; SMN2HIF1AMMP1 | |
| Ammonia Solution, Strong SCHEMBL340103 | 0.74 | SLC6A2 (0.52) | SLC6A2TAAR1SMN1; SMN2HIF1ARECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1635851-B1 | METHODS FOR TREATING COGNITIVE IMPAIRMENT AND IMPROVING COGNITION | COGNITION PHARMACEUTICALS LLC (US) | 2013-10-16 | — | — | EP | disclosed |
| US-20130231395-A1 | METHODS FOR TREATING ALZHEIMER'S DISEASE | COGNITION PHARMACEUTICALS, LLC (US) | 2013-09-05 | — | — | US | disclosed |
| US-20120142785-A1 | METHODS FOR TREATING ALZHEIMER'S DISEASE | COGNITION PHARMACEUTICALS LLC (US) | 2012-06-07 | — | — | US | disclosed |
| US-20110251175-A1 | Stigmine Conjugates for Substance Use Disorders | COLUCID PHARMACEUTICALS, INC. | 2011-10-13 | — | — | US | disclosed |
| US-20110144177-A1 | Carbamoyl Esters That Inhibit Cholinesterase And Release Pharmacologically Active Agents | COLUCID PHARMACEUTICALS, INC. | 2011-06-16 | — | — | US | disclosed |
| EP-2314571-A2 | Carbamoyl esters that inhibit cholinesterase and release pharmacologically active agents | CoLucid Pharmaceuticals, Inc. (US) | 2011-04-27 | — | — | EP | disclosed |
| US-7897639-B2 | Amine group that, upon hydrolysis, becomes a component of a pharmacologically active agent for treatment of nervous system disordres | COLUCID PHARMACEUTICALS, INC. (US) | 2011-03-01 | — | — | US | disclosed |
| US-7795307-B2 | Carbamoyl esters that inhibit cholinesterase and release pharmacologically active agents | COLUCID PHARMACEUTICALS, INC. (US) | 2010-09-14 | — | — | US | disclosed |
| US-20100022658-A1 | Methods for treating cognitive impairment in humans | COGNITION PHARMACEUTICALS LLC (US) | 2010-01-28 | — | — | US | disclosed |
| US-20100010097-A1 | Methods for treating mild cognitive impairment and alzheimer's disease | COGNITION PHARMACEUTICALS, LLC (US) | 2010-01-14 | — | — | US | disclosed |
| US-20070275959-A1 | Carbamoyl Esters That Inhibit Cholinesterase And Release Pharmacologically Active Agents | SENTION, INC. | 2007-11-29 | — | — | US | disclosed |
| US-20070197663-A1 | Methods of treating memory and cognitive impairments in humans following stroke and traumatic brain injury | EPSTEIN MEL H | 2007-08-23 | — | — | US | disclosed |
| US-7244769-B2 | Methods for treating an impairment in memory consolidation | COGNITION PHARMACEUTICALS, LLC (US) | 2007-07-17 | — | — | US | disclosed |
| US-20070117869-A1 | Methods for treating coginitive impairment and improving cognition | COGNITION PHARMACEUTICALS LLC | 2007-05-24 | — | — | US | disclosed |
| US-20070099999-A1 | Methods of treating depression | EPSTEIN MEL H | 2007-05-03 | — | — | US | disclosed |
| US-20070100000-A1 | Methods of providing neuroprotection | EPSTEIN MEL H | 2007-05-03 | — | — | US | disclosed |
| US-20060167111-A1 | Methods for treating an impairment in memory consolidation | PRIESTLEY, KATHERINE (GB) | 2006-07-27 | — | — | US | disclosed |
| US-20050096387-A1 | Carbamoyl esters that inhibit cholinesterase and release pharmacologically active agents | SENTION, INC. (US) | 2005-05-05 | — | — | US | disclosed |
| US-20050059743-A1 | Treatment with particular enantiomers levo-amphetamine or levo-methamphetamine without adverse side effects | SENTION, INC. (US) | 2005-03-17 | — | — | US | disclosed |
| US-20030232890-A1 | Methods for treating an impairment in memory consolidation | SENTION, INC. (US) | 2003-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251175-A1 | Stigmine Conjugates for Substance Use Disorders | TACR2, NPSR1, TACR3 | SLC6A2 33/4885TAAR1 37/4885SMN1; SMN2 1475/4885 |
| US-20030232890-A1 | Methods for treating an impairment in memory consolidation | PNMT, CHAT, DOT1L | SLC6A2 218/4885TAAR1 20/4885SMN1; SMN2 170/4885 |
| US-20050059743-A1 | Treatment with particular enantiomers levo-amphetamine or levo-methamphetamine without adverse side effects | COMT, PNMT, MAPT | SLC6A2 97/4885TAAR1 39/4885SMN1; SMN2 716/4885 |
| US-20110144177-A1 | Carbamoyl Esters That Inhibit Cholinesterase And Release Pharmacologically Active Agents | ACHE, BCHE, CHAT | SLC6A2 1079/4885TAAR1 1885/4885SMN1; SMN2 1224/4885 |
| US-20070099999-A1 | Methods of treating depression | HTR1A, HTR1D, PNMT | SLC6A2 146/4885TAAR1 35/4885SMN1; SMN2 935/4885 |
| US-20070275959-A1 | Carbamoyl Esters That Inhibit Cholinesterase And Release Pharmacologically Active Agents | ACHE, BCHE, CHAT | SLC6A2 1041/4885TAAR1 1772/4885SMN1; SMN2 1436/4885 |
| US-20070100000-A1 | Methods of providing neuroprotection | CHAT, PNMT, BDNF | SLC6A2 279/4885TAAR1 95/4885SMN1; SMN2 27/4885 |
| US-20070197663-A1 | Methods of treating memory and cognitive impairments in humans following stroke and traumatic brain injury | PNMT, COMT, MAP2 | SLC6A2 116/4885TAAR1 65/4885SMN1; SMN2 178/4885 |
| US-20060167111-A1 | Methods for treating an impairment in memory consolidation | PNMT, CHAT, METTL3 | SLC6A2 160/4885TAAR1 44/4885SMN1; SMN2 228/4885 |
| US-20070117869-A1 | Methods for treating coginitive impairment and improving cognition | COMT, PNMT, CHAT | SLC6A2 122/4885TAAR1 106/4885SMN1; SMN2 448/4885 |
| US-20130231395-A1 | METHODS FOR TREATING ALZHEIMER'S DISEASE | CHAT, ACHE, PNMT | SLC6A2 10/4885TAAR1 74/4885SMN1; SMN2 257/4885 |
| US-20050096387-A1 | Carbamoyl esters that inhibit cholinesterase and release pharmacologically active agents | ACHE, BCHE, CHAT | SLC6A2 1079/4885TAAR1 1885/4885SMN1; SMN2 1224/4885 |
| US-20100022658-A1 | Methods for treating cognitive impairment in humans | COMT, PNMT, CHAT | SLC6A2 120/4885TAAR1 96/4885SMN1; SMN2 113/4885 |
| US-20100010097-A1 | Methods for treating mild cognitive impairment and alzheimer's disease | CHAT, COMT, PNMT | SLC6A2 159/4885TAAR1 89/4885SMN1; SMN2 513/4885 |
| US-20120142785-A1 | METHODS FOR TREATING ALZHEIMER'S DISEASE | ACHE, PNMT, MAPT | SLC6A2 98/4885TAAR1 156/4885SMN1; SMN2 200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.